The U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
The most common side effects are nausea and vomiting, flushing, injection site reactions and headache. About 40% of patients in the clinical trials experienced nausea, most commonly with the first Vyleesi injection, and 13% needed medications for the treatment of nausea. About 1% of patients reported darkening of the gums and parts of the skin, of the face and breasts, which did not go away in about half the patients after stopping treatment. Patients with dark skin were more likely to develop this side effect.
Vyleesi may significantly decrease the levels of naltrexone in the blood.
Vyleesi increased blood pressure after dosing, which usually resolved within 12 hours. Vyleesi should not be used in patients with high blood pressure that is uncontrolled or in those with known cardiovascular disease.
No comments:
Post a Comment